Literature DB >> 9426334

Activated oxazaphosphorines are transported predominantly by erythrocytes.

M S Highley1, D Schrijvers, A T Van Oosterom, P G Harper, G Momerency, K Van Cauwenberghe, R A Maes, E A De Bruijn, M B Edelstein.   

Abstract

PURPOSE: Oxazaphosphorines are metabolised by a variety of pathways, one of which leads to activation and the formation of alkylating compounds. However, the transport forms conveying activated oxazaphosphorines to the tumour cell have not been fully characterised. There is increasing recognition of the importance of the erythrocyte as a carrier of compounds in the circulation, and we have recently described higher concentrations of 4-hydroxycyclophosphamide within the erythrocyte compartment compared to plasma. We have now determined the concentrations of ifosfamide and seven of its metabolites in the plasma and erythrocytes of patients receiving a six-hour intravenous infusion of ifosfamide. PATIENTS AND METHODS: Red cells from five patients, receiving a total of eight cycles of ifosfamide, were separated from plasma using the MESED instrument, and analysis of red cells and plasma performed using Gas Chromatography-Mass Spectrometry (GC/MS).
RESULTS: The concentration of all compounds in the erythrocyte compartment was higher than or equal to those in plasma, and isophosphoramide mustard and carboxyifosfamide showed a particular affinity for the erythrocyte. The red cell fraction can contain as much as 77% of the total blood concentration of isophosphoramide mustard.
CONCLUSIONS: Erythrocyte associated isophosphoramide mustard is an important transport form of activated ifosfamide. Red cells may have a role in the delivery of activated oxazaphosphorines to tissues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426334     DOI: 10.1023/a:1008261203803

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

Review 1.  Role of red blood cells in pharmacokinetics of chemotherapeutic agents.

Authors:  Dirk Schrijvers
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.

Authors:  Diane M Calinski; Haoming Zhang; Susan Ludeman; M Eileen Dolan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2015-05-01       Impact factor: 3.922

Review 3.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 4.  Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.

Authors:  Karen I Sweiss; Rakesh Beri; Stacy S Shord
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

Authors:  Duan Wang; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2012-04-01       Impact factor: 11.413

Review 6.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

7.  CITCO as an Adjuvant Facilitates CHOP-Based Lymphoma Treatment in hCAR-Transgenic Mice.

Authors:  Ritika Kurian; William Hedrich; Bryan Mackowiak; Linhao Li; Hongbing Wang
Journal:  Cells       Date:  2020-11-21       Impact factor: 6.600

8.  Genetic Polymorphism of GSTP-1 Affects Cyclophosphamide Treatment of Autoimmune Diseases.

Authors:  Péter Hajdinák; Melinda Szabó; Emese Kiss; Lili Veress; Lívius Wunderlich; András Szarka
Journal:  Molecules       Date:  2020-03-28       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.